Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study.
McCarthy PL, Attwood KM, Liu X, Chen GL, Minderman H, Alousi A, Bashey A, Lowsky R, Miklos DB, Hansen J, Westervelt P, Yanik G, Waller EK, Howard A, Blazar BR, Wallace PK, Reshef R, Horowitz MM, Maziarz RT, Levine JE, Mohammadpour H. McCarthy PL, et al. Among authors: minderman h. Bone Marrow Transplant. 2024 Mar;59(3):334-343. doi: 10.1038/s41409-023-02168-0. Epub 2023 Dec 18. Bone Marrow Transplant. 2024. PMID: 38110620 Free PMC article.
Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influx.
Gandhi S, Opyrchal M, Grimm MJ, Slomba RT, Kokolus KM, Witkiewicz A, Attwood K, Groman A, Williams L, Tarquini ML, Wallace PK, Soh KT, Minderman H, Maguire O, O'Connor TL, Early AP, Levine EG, Kalinski P. Gandhi S, et al. Among authors: minderman h. J Immunother Cancer. 2023 Nov;11(11):e007381. doi: 10.1136/jitc-2023-007381. J Immunother Cancer. 2023. PMID: 37963636 Free PMC article.
NK Receptors Replace CD28 As the Dominant Source of Signal 2 for Cognate Recognition of Cancer Cells by TAA-specific Effector CD8+ T Cells.
Dong B, Obermajer N, Tsuji T, Matsuzaki J, Bonura C, Withers H, Long M, Chavel C, Olejniczak SH, Minderman H, Edwards RP, Storkus WJ, Romero P, Kalinski P. Dong B, et al. Among authors: minderman h. Res Sq [Preprint]. 2023 Oct 19:rs.3.rs-3399211. doi: 10.21203/rs.3.rs-3399211/v1. Res Sq. 2023. PMID: 37886562 Free PMC article. Preprint.
Short-Term Storage of Mobilized Peripheral Blood Stem Cells in a Closed System Changes the Microenvironment and May Affect the Quantity of CD34+ and CD34+CD38-CD45RA-CD90+ Cells.
Elshoury A, Maguire O, Conway A, Tario J, Soh KT, Ross M, Hahn T, Becker J, Wallace P, McCarthy PL, Minderman H, Chen GL. Elshoury A, et al. Among authors: minderman h. Transplant Cell Ther. 2023 Feb;29(2):112.e1-112.e9. doi: 10.1016/j.jtct.2022.11.021. Epub 2022 Nov 24. Transplant Cell Ther. 2023. PMID: 36436782 Free PMC article.
Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101).
Babiker H, Borazanci E, Subbiah V, Agarwala S, Algazi A, Schachter J, Lotem M, Maurice-Dror C, Hendler D, Rahimian S, Minderman H, Haymaker C, Mahadevan D, Bernatchez C, Murthy R, Hultsch R, Kaplan N, Woodhead G, Hennemeyer C, Chunduru S, Anderson PM, Diab A, Puzanov I. Babiker H, et al. Among authors: minderman h. Clin Cancer Res. 2022 Dec 1;28(23):5079-5087. doi: 10.1158/1078-0432.CCR-21-4486. Clin Cancer Res. 2022. PMID: 35917516
Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer.
Fountzilas C, Bajor DL, Mukherjee S, Saltzman J, Witkiewicz AK, Maguire O, Minderman H, Nambiar R, Rosenheck HR, Knudsen ES, Muhitch JB, Abrams SI, Wang C, Hutson AD, Attwood K, Hicks KA, Jurcevic JA, Kalinski P, Iyer R, Boland PM. Fountzilas C, et al. Among authors: minderman h. Clin Cancer Res. 2021 Dec 15;27(24):6726-6736. doi: 10.1158/1078-0432.CCR-21-1650. Epub 2021 Oct 13. Clin Cancer Res. 2021. PMID: 34645646 Free PMC article. Clinical Trial.
Induction of cell death in ovarian cancer cells by doxorubicin and oncolytic vaccinia virus is associated with CREB3L1 activation.
Mistarz A, Graczyk M, Winkler M, Singh PK, Cortes E, Miliotto A, Liu S, Long M, Yan L, Stablewski A, O'Loughlin K, Minderman H, Odunsi K, Rokita H, McGray AJR, Zsiros E, Kozbor D. Mistarz A, et al. Among authors: minderman h. Mol Ther Oncolytics. 2021 Apr 29;23:38-50. doi: 10.1016/j.omto.2021.04.014. eCollection 2021 Dec 17. Mol Ther Oncolytics. 2021. PMID: 34632049 Free PMC article.
Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments.
Bhatta M, Shenoy GN, Loyall JL, Gray BD, Bapardekar M, Conway A, Minderman H, Kelleher RJ Jr, Carreno BM, Linette G, Shultz LD, Odunsi K, Balu-Iyer SV, Pak KY, Bankert RB. Bhatta M, et al. Among authors: minderman h. J Immunother Cancer. 2021 Oct;9(10):e003148. doi: 10.1136/jitc-2021-003148. J Immunother Cancer. 2021. PMID: 34599030 Free PMC article.
In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T, Makino K, Kajihara R, Yokoi T, Araki R, Abe M, Minderman H, Chang AE, Odunsi K, Ito F. Oba T, et al. Among authors: minderman h. J Immunother Cancer. 2021 May;9(5):e002432. doi: 10.1136/jitc-2021-002432. J Immunother Cancer. 2021. PMID: 34049930 Free PMC article.
82 results